

Zevra is a rare disease therapeutics company driven by science, data and patients' unmet needs to create transformational therapies for diseases with limited or no treatment options.

Nimble and determined, Zevra pushes boundaries beyond what is possible to advance new therapies that meaningfully improve patients' lives.



#### **ZEVRA'S APPROACH**

We are driven by a patient-centric approach, coupled with outside-the-box strategies to develop promising product candidates for rare diseases.

- Our team is a rare mix of expert scientists, patient advocates, development strategists, medical leaders, commercialization specialists, and business development gurus with a proven record of bringing new therapies to patients.
- We specialize in a data-driven approach, while carefully balancing patient needs, to advance therapies and find solutions to overcome complex clinical and regulatory challenges.

#### **ZEVRA'S COMMITMENT**

We are committed to making promising rare disease therapies available to patients with the aim of improving their quality of life.

- Zevra is Greek for zebra, the official symbol of rare disease, a daily reminder of the unique challenges that people affected by rare diseases face, and our inspiration to bring much needed treatment options to this community.
- To learn more about our commitment to the rare disease community and our Expanded Access Policy, visit our [Expanded Access Policy](#) page.



*Expanded Access Policy*

More information is available at [www.Zevra.com](http://www.Zevra.com)

## RARE DISEASE LEADERSHIP

Zevra's patient advocacy engagement and collaborations in rare disease areas that we support, **such as Idiopathic Hypersomnia (IH), Narcolepsy and Niemann-Pick Disease Type C (NPC), are critical in informing our approach to clinical studies, disease education, and regulatory strategy.**

Zevra is actively working to expand understanding of rare diseases and their impact in to patients in the real world setting through collaborations with advocacy research consortiums and disease registries.

## ZEVRA'S PIPELINE

Our scientific expertise, creative approach to clinical and regulatory challenges, and transparent approach to data communications have produced a late-stage rare disease clinical pipeline and an FDA approved treatment.

PRODUCT CANDIDATE	INDICATION	PHASE 1	PHASE 2	PHASE 3	NDA SUBMISSION
<b>NIEMANN-PICK DISEASE TYPE C (NPC) PROGRAM</b>					
<b>Arimoclomol</b> <i>Orally delivered, first-in-class investigational product candidate</i>	Niemann-Pick Disease Type C (NPC)				
<b>RARE SLEEP DISORDERS PROGRAM</b>					
<b>KP1077</b> <i>serdexmethylphenidate is a prodrug candidate of dexmethylphenidate for sleep disorders</i>	Idiopathic Hypersomnia (IH)				
	Narcolepsy				
MARKETED PRODUCT	INDICATION	COMMERCIAL PARTNER			
<b>ADHD COMMERCIAL PRODUCT</b>					
<b>AZSTARYS®</b> <i>serdexmethylphenidate and dexmethylphenidate</i>	Attention Deficit Hyperactivity Disorder (ADHD) in patients age six and older	Corium Inc.			

AZSTARYS® is a federally controlled substance (CII) because it can be abused or lead to dependence. Keep AZSTARYS® in a safe place to prevent misuse and abuse. Selling or giving away AZSTARYS® may harm others and is against the law.

For more information about our FDA approved treatment in partnership with Corium, Inc., AZSTARYS®, visit our [Science & Pipeline](#) page.

Beyond our product pipeline, we are committed to building a portfolio of drug candidates that addresses rare diseases with unmet needs.



Science & Pipeline

More information is available at [www.Zevra.com](http://www.Zevra.com)